A Study of HMPL-689 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 23, 2016

Primary Completion Date

October 26, 2016

Study Completion Date

February 28, 2017

Conditions

Healthy Volunteers

Interventions

DRUG

HMPL-689

selective PI3Kδ inhibitor

DRUG

HMPL-689 placebo

placebo of HMPL-689

Trial Locations (1)

Nucleus Network, Melbourne

All Listed Sponsors

lead

Hutchison Medipharma Limited

INDUSTRY

NCT02631642 - A Study of HMPL-689 in Healthy Volunteers | Biotech Hunter | Biotech Hunter